Alcidion signs key contract with NSW Health

By Justin Ware. Published at May 20, 2019, in Technology

Alcidion Group (ASX:ALC) will build and integrate two key components for a proposed national Child Digital Health Record (CDHR), thanks to a new contract with NSW Health.

Under the agreement, ALC will deliver an operational Child Data Hub (CDH) and a NSW Health Jurisdictional Translator that will take data from operational systems and pass it onto the CDH.

The Child Digital Health Record is a proposed national scheme, which will be trialled in two NSW Health Districts. The cutting edge solutions developed by ALC will be hosted in a Microsoft Azure cloud environment and architected using the latest healthcare standards.

About Alcidion

Alcidion Group (ASX:ALC) aims to make healthcare better, with an array of smart intuitive solutions that meet the needs of hospital and healthcare providers worldwide.

The Group consists of three pillars: Alcidion Corporation, Patientrack and Smartpage, and MKM Health (an IT solutions and services provider).

Each component offers a complimentary selection of skills and products that create a truly unique offering in the global healthcare market.

With over 25 years of combined healthcare experience, ALC brings together the best in technology and market knowledge to deliver solutions that truly matter in the healthcare sector.

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Thanks for subscribing!